NOVATIVE
NOVATIVE (NCT00328653) was a phase II/III, multicentre, randomised, double-masked, parallel-group, double-ranging controlled trial. The study was conducted at 21 sites in 6 countries. The study included 2 treatment periods. In the first 4-week period, patients (